DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Summary for Patent: 9,920,311
|Abstract:||Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.|
|Inventor(s):||Abribat; Thierry (Sainte Foy les Lyon, FR)|
|Assignee:||Jazz Pharmaceuticals II SAS (Lyons, FR)|
|Patent Claims:||1. A conjugate comprising an L-asparaginase from Erwinia chrysanthemi having at least 90% sequence identity to the amino acid of SEQ ID NO:1 and conjugated to at least one
polyethylene glycol (PEG) molecule, wherein the at least one PEG has a molecular weight less than 5000, 4000, 3000, or 2500 Da and the conjugate has at least fifty times more in vivo L-asparaginase activity compared to an Erwinia chrysanthemi
L-asparaginase not conjugated to PEG.
2. The conjugate of claim 1, wherein said L-asparaginase has at least 95% to 99% sequence identity to the amino acid of SEQ ID NO: 1.
3. The conjugate of claim 1, wherein said L-asparaginase comprises the amino acid of SEQ ID NO: 1.
4. The conjugate of claim 1, wherein the PEG is covalently linked to one or more amino groups of said L-asparaginase.
5. The conjugate of claim 4, wherein the PEG molecules are covalently linked to at least from about 40% to about 100% of the accessible amino groups of said L-asparaginase.
6. The conjugate of claim 1 having the formula: Asp-[NH--CO--(CH.sub.2)x-CO--NH-PEG]n wherein Asp is the L-asparaginase, NH is one or more of the NH groups of the lysine residues and/or the N-terminus in the Asp, PEG is a polyethylene glycol moiety, n is a number that represents at least 40% to 100% of the accessible amino groups in the Asp, and x is an integer ranging from 1 to 8.
7. The conjugate of claim 1, wherein said PEG is monomethoxy-polyethylene glycol.
8. The conjugate of claim 1, wherein said conjugate has at least sixty, seventy, eighty, ninety or one-hundred times more in vivo L-asparaginase activity compared to an Erwinia chrysanthemi L-asparaginase not conjugated to PEG.
9. The conjugate of claim 1, wherein the conjugate has increased residual enzymatic activity in vivo when compared to Erwinia chrysanthemi L-asparaginase conjugated to at least one PEG molecule with a molecular weight of 10,000 Da.
10. The conjugate of claim 1, wherein the L-asparaginase does not cross-react with antibodies which react with Escherichia coli L-asparaginase.
11. The conjugate of claim 1 comprising an L-asparaginase from Erwinia chrysanthemi consisting of the amino acid of SEQ ID NO: 1 and the conjugate has reduced immunogenicity when administered to a human subject hypersensitive to Escherichia coli L-asparaginase.
12. The conjugate of claim 1, wherein the conjugate has an in vitro L-asparaginase activity of at least 60%, 70%, 80%, or 87% of an L-asparaginase not conjugated to PEG.
13. The conjugate of claim 1, wherein said PEG has a molecular weight of less than 5000 Da.
14. The conjugate of claim 1, wherein the PEG molecules are covalently linked to at least 60%, 70%, 80%, 90% or 100% of the accessible amino groups of said L-asparaginase.
Summary for Patent: See Pricing
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|PCT/EP2010/054156||Mar 30, 2010|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Merck||ELSPAR||asparaginase||VIAL||101063||001||1978-01-10||See Pricing||Jazz Pharmaceuticals II SAS (Lyons, FR)||2030-03-30||RX||search|
|Jazz Pharms Inc||ERWINAZE||asparaginase erwinia chrysanthemi||INJECTABLE; INJECTION||125359||001||2011-11-18||See Pricing||Jazz Pharmaceuticals II SAS (Lyons, FR)||2030-03-30||RX||Orphan||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.